2015, from https://www.merck.com/news/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma/ [
该研究纳入了EGFR/ALK/ROS1/BRAF阴性的PD-L1高表达(TPS≥50%)晚期NSCLC患者,一线使用M7824或帕博利珠单抗治疗。 在回顾该研究的数据时,独立数据监测委员会(IDMC)于2021年1月19日建议停止该临床试验,因为该研究不太可能达到主要疗效终点(...
https://www.smmttx.com/ivonescimab-smt112/ https://seekingalpha.com/article/4737304-merck-keytrudas-sales-projections-outweigh-competitive-and-patent-risks https://akesobio.com/ https://www.lanovamedicines.com/
Wang J, Lu S, Yu X, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.https://www.merck.com/research/product-pipeline/.Johnson...
近期,FDA批准了Merck的抗PD-1免疫治疗药物KEYTRUDA® (pembrolizumab)联合化疗培美曲塞和卡铂作为转移性非鳞癌NSCLC患者的一线治疗,无论PD-L1的表达如何。FDA的审批是基于肿瘤的客观缓解率ORR以及无进展生存期PFS的小样本II期临床数据,并且没有提供总生存OS的最终对比数据。
1.FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer. 2.https://www.merck.com/news/merck-to-acquire-velosbio/. ...
参考出处: 1、https://www.fda.gov/Drugs/InformationOnDrugs/default.htm 2、http://www.msd.com/ 3、https://www.bms.com/ 4、https://www.gene.com/ 5、http://www.merck.com/index.html
1.https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-in-first-line-advanced-or-unresectable-biliary-tract-cancer-in-keynote-966 2.Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, ...
The study was funded by Moderna Inc. of Cambridge, Mass., and Merck of Rahway, NJ. mRNA-4157/V940 is being jointly developed and commercialized by Moderna and Merck. Merck is the manufacturer of pembrolizumab. About 1.3 million Americans are currently diagnosed with some form of melanoma.